Akribion Genomics
Company Type: CRO
Main focus: Discovery and engineering of novel nucleases
Company stage: Pre-clinical
Diseases: Cancer
Genome-editing tool: Proprietary G-dases® nucleases
Funding stage: sub-section of BRAIN Biotech AG (IPO: BNN)
Location: Zwingenberg, Germany
Website: https://www.akribion-genomics.com/
Pipeline:
Partners: BRAIN Biotech AG
As a brand name of BRAIN Biotech AG, Akribion Genomics focuses on developing novel CRISPR nucleases into a new class of genetics-based cancer therapies and advanced genome-editing tools, powered by the BRAIN Biotech AG BioIncubator. Akribion Genomics’ CRISPR-based gene-editing technology platform features distinct technology families (G-dases®) with broad application in Industrial Biotechnology and Agriculture.